Score Overview
Explore the 2021 public Archive ranking →
Where Novartis AG ADR has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. NVS does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 145.71 | — |
1 Year2025-09-29 | $ 120.43 | 20.99% |
5 Years2021-09-29 | $ 68.74 | 111.97% |
10 Years2016-09-29 | $ 49.26 | 195.80% |
20 Years2006-09-29 | $ 25.55 | 470.28% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 145.71 | $ 120.43 | $ 68.74 | $ 49.26 | $ 25.55 |
| Return | — | 20.99% | 111.97% | 195.80% | 470.28% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 55.63B | $ 12.75B | $ 7.69B |
| 2025 | $ 54.81B | $ 14.05B | $ 11.59B |
| 2024 | $ 51.72B | $ 11.94B | $ 13.35B |
| 2023 | $ 46.66B | $ 14.85B | $ 13.96B |
| 2022 | $ 43.46B | $ 6.95B | $ 18.61B |
| 2021 | $ 43.97B | $ 24.02B | $ 28.11B |
| 2020 | $ 49.89B | $ 8.07B | $ 11.56B |
| 2019 | $ 48.67B | $ 11.73B | $ 11.44B |
| 2018 | $ 46.09B | $ 12.61B | $ 15.96B |
| 2017 | $ 43.40B | $ 7.70B | $ 9.48B |
| 2016 | $ 49.43B | $ 6.71B | $ 7.77B |
| 2015 | $ 50.38B | $ 17.78B | $ 5.44B |
| 2014 | $ 53.63B | $ 10.21B | $ 13.86B |
| 2013 | $ 52.71B | $ 9.17B | $ 9.22B |
| 2012 | $ 51.97B | $ 9.27B | $ 8.11B |
| 2011 | $ 59.37B | $ 8.94B | $ 5.07B |
| 2010 | $ 51.56B | $ 9.79B | $ 8.13B |
| 2009 | $ 45.10B | $ 8.40B | $ 17.44B |
| 2008 | $ 42.58B | $ 8.19B | $ 6.11B |
| 2007 | $ 38.94B | $ 11.94B | $ 13.20B |
| 2006 | $ 35.10B | $ 7.17B | $ 7.95B |
| 2005 | $ 29.75B | $ 6.13B | $ 10.93B |
| 2004 | $ 27.27B | $ 5.36B | $ 14.59B |
| 2003 | $ 24.93B | $ 4.74B | $ 13.25B |
| 2002 | $ 20.87B | $ 4.72B | $ 12.57B |
| 2001 | $ 18.76B | $ 3.83B | $ 13.18B |
| 2000 | $ 22.18B | $ 4.46B | $ 12.51B |
| 1999 | $ 20.38B | $ 4.18B | $ 10.26B |
| 1998 | $ 23.03B | $ 4.36B | $ 9.69B |
Novartis AG ADR fundamental performance
Between 2020 and 2025, revenue grew from $ 49.89B to $ 54.81B and net income grew from $ 8.07B to $ 14.05B. Revenue increased in 4 of those 5 years; net income in 2.
Across Novartis AG ADR's full reported history, from 1998 to 2025, revenue grew from $ 23.03B to $ 54.81B and net income grew from $ 4.36B to $ 14.05B. Revenue increased in 71% of the years measured; net income in 61%.
Novartis AG ADR currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Membership
Explore NVS with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
